Global Information
회사소개 | 문의 | 비교리스트

고셰병(III형) : 파이프라인 리뷰

Gaucher Disease Type III - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 410974
페이지 정보 영문 36 Pages
가격
US $ 2,000 ₩ 2,433,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,866,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,299,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


고셰병(III형) : 파이프라인 리뷰 Gaucher Disease Type III - Pipeline Review, H2 2016
발행일 : 2016년 12월 페이지 정보 : 영문 36 Pages

고셰병(III형)은 만성적 신경장애성 고셰병(아급성 신경장애성 고셰병)으로도 알려져 있습니다. 증상은 지적 기능 저하, 운동실조, 마이오클로누스 발작 등을 볼 수 있습니다. 이 질환은 글루코세레브로시드라고 불리는 지방질 축적이 원인으로 발병하며, 효소보충요법으로 치료합니다.

고셰병(III형)의 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보 등을 최신 뉴스와 발표와 함께 전해드립니다.

서론

  • 조사 범위

고셰병(III형) 개요

치료제 개발

  • 파이프라인 제품 : 개요

기업에서 개발중인 치료제

파이프라인 제품 상황 개요

  • 임상시험 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

치료제 개발 참여 기업

  • Actelion Ltd
  • Belrose Pharma Inc
  • Erad Therapeutics Inc
  • Genzyme Corp
  • Shire Plc

치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개요

  • ambroxol
  • ibiglustat
  • miglustat
  • 고셰병(I형 및 III형)용 Recombinant Protein
  • Recombinant Protein

휴지 상태인 프로젝트

부록

도표

LSH 17.01.23

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gaucher Disease Type III - Pipeline Review, H2 2016, provides an overview of the Gaucher Disease Type III (Genetic Disorders) pipeline landscape.

Gaucher disease type III also known as chronic neuronopathic Gaucher disease (subacute form of neuronopathic Gaucher disease). Symptoms include mental deterioration, ataxia, and myoclonic seizures. The cause of Gaucher disease III is the accumulation of a fatty material called glucocerebroside (also known as glucosylceramide) Treatment includes enzyme replacement therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gaucher Disease Type III - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gaucher Disease Type III (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gaucher Disease Type III (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gaucher Disease Type III and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 3, 1 and 1 respectively.

Gaucher Disease Type III (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gaucher Disease Type III (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Gaucher Disease Type III (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gaucher Disease Type III (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gaucher Disease Type III (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gaucher Disease Type III (Genetic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gaucher Disease Type III (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gaucher Disease Type III (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gaucher Disease Type III Overview
  • Therapeutics Development
    • Pipeline Products for Gaucher Disease Type III - Overview
  • Gaucher Disease Type III - Therapeutics under Development by Companies
  • Gaucher Disease Type III - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Gaucher Disease Type III - Products under Development by Companies
  • Gaucher Disease Type III - Companies Involved in Therapeutics Development
    • Actelion Ltd
    • Belrose Pharma Inc
    • Erad Therapeutics Inc
    • Genzyme Corp
    • Shire Plc
  • Gaucher Disease Type III - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ambroxol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibiglustat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • miglustat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Type I and Type III Gaucher's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • velaglucerase alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Gaucher Disease Type III - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Gaucher Disease Type III, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Gaucher Disease Type III - Pipeline by Actelion Ltd, H2 2016
  • Gaucher Disease Type III - Pipeline by Belrose Pharma Inc, H2 2016
  • Gaucher Disease Type III - Pipeline by Erad Therapeutics Inc, H2 2016
  • Gaucher Disease Type III - Pipeline by Genzyme Corp, H2 2016
  • Gaucher Disease Type III - Pipeline by Shire Plc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Gaucher Disease Type III - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Gaucher Disease Type III, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top
전화 문의
F A Q